Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NovaMin Technology is a medical technology company that developed a proprietary bioactive glass used primarily in oral healthcare. The company's core technology, a calcium sodium phosphosilicate compound, was originally designed for bone regeneration but was successfully repurposed to treat dentin hypersensitivity. When exposed to saliva, NovaMin releases calcium and phosphate ions that form a protective hydroxyapatite-like layer over exposed dentin tubules. This mechanism provides rapid and long-lasting relief from tooth sensitivity. In 2010, the company was acquired by GSK for approximately $135 million. Today, NovaMin is a key active ingredient in the Sensodyne Repair & Protect toothpaste line and other professional dental products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NovaMin Technology.